文献速递神经肿瘤

低级别胶质瘤老年患者的诊疗模式与治疗结局:50年经验

Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience.
PubMed 文献 · J Neurooncol · 2017-04-21

该研究纳入梅奥诊所1960至2011年诊断的94例55岁及以上WHO II级低级别胶质瘤成人患者,按术后MRI常规使用前后分组,比较表现、治疗与结局变化。中位随访11.4年,中位无进展生存期3.0年、总生存期4.1年,现代组无进展生存期与总生存期均未改善。

要点

  • 老年低级别胶质瘤患者现代组无进展生存期与总生存期均未改善。
  • 多变量分析中星形细胞瘤组织学、强化和次全切除/活检与较差无进展生存期相关。
  • 多变量分析中星形细胞瘤组织学、深部位置、强化和次全切除/活检与较差总生存期相关。

核心结论

  • 尽管有报道称年轻患者在现代治疗下结局改善,但老年低级别胶质瘤患者的结局未显著改善。
  • 需要基于分子基因分型的进一步努力来改善结局,以确定合理的治疗强化策略。

研究设计与样本

  • 回顾性纳入梅奥诊所1960至2011年诊断的94例55岁及以上WHO II级低级别胶质瘤成人患者,按术后MRI常规使用前后分为组I(1960-1989年)和组II(1990-2011年)。
  • 中位随访11.4年,病理诊断包括星形细胞瘤55%、混合少突星形细胞瘤18%和少突胶质细胞瘤27%。

主要发现

  • 全切除占10%,根治性次全切除占6%,次全切除占20%,仅活检占64%;术后放疗占77%。
  • 现代组接受全切除/根治性次全切除的患者更多(20% vs 7%),但差异无统计学意义。
  • 中位无进展生存期3.0年,5年和10年无进展生存率分别为31%和10%。
  • 中位总生存期4.1年,5年和10年总生存率分别为43%和17%。
  • 现代组无进展生存期和总生存期均未改善。

关键数值与推荐

  • 多变量分析中与较差无进展生存期相关的因素包括星形细胞瘤组织学、对比剂强化和次全切除/活检。
  • 多变量分析中与较差总生存期相关的因素包括星形细胞瘤组织学、深部位置、对比剂强化和次全切除/活检。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this study was to identify changes in presentation, treatment and outcomes of older patients with low-grade glioma (LGG) over the past 50 years. 94 adults aged 55 or older upon diagnosis of a WHO grade II LGG at Mayo Clinic between 1960 and 2011 were included and grouped by those diagnosed before (group I: 1960-1989) and after (group II: 1990-2011) the routine use of post-operative MRI. Median follow-up was 11.4 years. Pathologic diagnoses included astrocytoma in 55%, mixed oligoastrocytoma in 18% and oligodendroglioma in 27%. Gross total resection (GTR) was achieved in 10%, radical subtotal resection (rSTR) in 6%, subtotal resection (STR) in 20% and biopsy only in 64%. Post-operative radiotherapy (PORT) was given in 77%. More patients in the modern era received GTR/rSTR (20 vs. 7%), though the difference was not statistically significant. Median progression-free survival (PFS) was 3.0 years, with 5- and 10-year PFS rates of 31 and 10%, respectively. Median, 5- and 10-year overall survival (OS) was 4.1 years, 43 and 17%, respectively. PFS and OS did not improve in the modern era. Factors negatively associated with PFS on multivariate analysis included astrocytoma histology, contrast enhancement and STR/biopsy. Factors associated with poor OS on multivariate analysis included astrocytoma histology, deep location, contrast enhancement and STR/biopsy. Despite reports of improving outcomes for younger patients treated in the modern era, outcomes have not significantly improved for older patients. Further efforts to improve outcomes based on molecular genotyping are needed to determine a rational strategy for treatment intensification.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Youland RS, Schomas DA, Brown PD, et al. Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience. J Neurooncol. 2017. PMID: 28432585. doi:10.1007/s11060-017-2439-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。